Changes of immune cells and inflammatory factors in psoriasis patients treated with secukizumab

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064706

Enrollment

Unknown

Registered

2022-10-15

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Intervention Group:Secukinumab

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed with psoriasis; 2. Comply with the indications for the application of biological agents; 3. PASI score>=3 points; 4. Age>=16 years old.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating patients; 2. Patients who have been using biological agents in the past six months; 3. Patients who have undergone other psoriasis treatment regimens in the past month; 4. Patients with tuberculosis, hepatitis B and other infectious diseases and tumors.

Design outcomes

Primary

Measure	Time frame
Treg/TH1/TH2/TH17 immune cells;inflammation factors, IFN-??TNF-a?IL-10?IL-12?IL-17?IL-23 ect;Galectin-1, -3, -7;	—

Countries

China

Contacts

Public ContactChunhong Zhang

The Second Hospital of Shandong University

aliu133@163.com+86 17660083312

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026